BR112019000486A2 - composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase - Google Patents

composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase

Info

Publication number
BR112019000486A2
BR112019000486A2 BR112019000486-6A BR112019000486A BR112019000486A2 BR 112019000486 A2 BR112019000486 A2 BR 112019000486A2 BR 112019000486 A BR112019000486 A BR 112019000486A BR 112019000486 A2 BR112019000486 A2 BR 112019000486A2
Authority
BR
Brazil
Prior art keywords
alkyl
cycloalkyl
treating
preventing
compound
Prior art date
Application number
BR112019000486-6A
Other languages
English (en)
Inventor
Stuart Jessiman Alan
Stephen Johnson Patrick
Maansson Kristoffer
Dahl Sørensen Morten
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of BR112019000486A2 publication Critical patent/BR112019000486A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

a presente invenção se refere a um composto de acordo com a fórmula geral (i), em que x representa n ou ch; r1 é -cn, (c1?c6)alquil, (c3?c7)cicloalquil, heterocicloalquil (com 3 a 7 membros), heteroaril (com 5 a 6 membros), (c3?c7)cicloalquil(c1?c4)alquil, heterocicloalquil (com 3 a 7 membros)-(c1?c4)alquil ou heteroaril (com 5 a 6 membros)-(c1?c4)alquil; r2 é halogênio, ciano, (c1?c4)alquil ou (c3?c7)cicloalquil; r3 é halogênio, ciano, (c1?c4)alquil, (c1?c4)haloalquil ou (c3?c7)cicloalquil; r4 é (c1?c4)alquil ou (c1?c4)haloalquil; r5 é (c1?c6)alquil, (c3?c7)cicloalquil, (c1?c6)alquil-(c3?c7)cicloalquil, (c3?c7)cicloalquil-(c1?c6)alquil, heterocicloalquil (com 3 a 7 membros), fenil, heteroaril (com 5 a 6 membros) ou -ora. a invenção se refere ainda aos referidos compostos para uso em terapia, a composições farmacêuticas compreendendo os referidos compostos e a intermediários para a preparação dos referidos compostos.
BR112019000486-6A 2016-07-13 2017-07-11 composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase BR112019000486A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16020268 2016-07-13
EP16020268.5 2016-07-13
PCT/EP2017/067390 WO2018011201A1 (en) 2016-07-13 2017-07-11 Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Publications (1)

Publication Number Publication Date
BR112019000486A2 true BR112019000486A2 (pt) 2019-04-24

Family

ID=56511303

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000486-6A BR112019000486A2 (pt) 2016-07-13 2017-07-11 composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase

Country Status (21)

Country Link
US (2) US10662181B2 (pt)
EP (1) EP3484880B1 (pt)
JP (1) JP7016344B2 (pt)
KR (1) KR102490140B1 (pt)
CN (1) CN109476653B (pt)
AU (1) AU2017294969B2 (pt)
BR (1) BR112019000486A2 (pt)
CA (1) CA3030370A1 (pt)
DK (1) DK3484880T3 (pt)
ES (1) ES2834009T3 (pt)
IL (1) IL264141B (pt)
MX (1) MX2019000361A (pt)
MY (1) MY196990A (pt)
PL (1) PL3484880T3 (pt)
PT (1) PT3484880T (pt)
RU (1) RU2771280C2 (pt)
SA (1) SA519400868B1 (pt)
SG (1) SG11201811107WA (pt)
UA (1) UA123330C2 (pt)
WO (1) WO2018011201A1 (pt)
ZA (1) ZA201808436B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662181B2 (en) * 2016-07-13 2020-05-26 Leo Pharma A/S Heteroaromatic modulators of the retinoid-related orphan receptor gamma
CN111825654A (zh) * 2019-04-19 2020-10-27 北京酷瓴生物技术有限公司 苯甲烯哌啶衍生物及其制备方法、中间体和用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS244821B2 (en) 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
FR2879381B1 (fr) 2004-12-15 2008-12-26 Thales Sa Systeme de distribution quantique de cle de cryptage a variables continues
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
EP2511275A1 (en) * 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
WO2014086894A1 (en) * 2012-12-06 2014-06-12 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
RU2016119662A (ru) * 2013-11-05 2017-12-11 Ф. Хоффманн-Ля Рош Аг ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc
CA2950220A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
KR20170008852A (ko) * 2014-05-28 2017-01-24 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 신규 화합물
WO2015180612A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
US10662181B2 (en) * 2016-07-13 2020-05-26 Leo Pharma A/S Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Also Published As

Publication number Publication date
EP3484880A1 (en) 2019-05-22
RU2019103883A (ru) 2020-08-13
US10934282B2 (en) 2021-03-02
UA123330C2 (uk) 2021-03-17
JP2019521137A (ja) 2019-07-25
AU2017294969B2 (en) 2021-03-25
CN109476653A (zh) 2019-03-15
WO2018011201A1 (en) 2018-01-18
MX2019000361A (es) 2019-05-23
KR102490140B1 (ko) 2023-01-19
NZ749301A (en) 2021-03-26
CA3030370A1 (en) 2018-01-18
PT3484880T (pt) 2020-12-07
CN109476653B (zh) 2022-04-22
AU2017294969A1 (en) 2019-01-17
SG11201811107WA (en) 2019-01-30
IL264141B (en) 2021-09-30
SA519400868B1 (ar) 2022-06-13
US20200291010A1 (en) 2020-09-17
IL264141A (en) 2019-02-28
JP7016344B2 (ja) 2022-02-04
ES2834009T3 (es) 2021-06-16
ZA201808436B (en) 2020-05-27
KR20190026872A (ko) 2019-03-13
PL3484880T3 (pl) 2021-04-06
US10662181B2 (en) 2020-05-26
RU2771280C2 (ru) 2022-04-29
EP3484880B1 (en) 2020-09-02
MY196990A (en) 2023-05-17
US20190284177A1 (en) 2019-09-19
DK3484880T3 (da) 2020-11-09
RU2019103883A3 (pt) 2020-09-23

Similar Documents

Publication Publication Date Title
CU20190045A7 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas que son inhibidores de la dihidroorotato deshidrogenasa (dhodh) útiles para el tratamiento o prevención de trastornos hiperproliferativos e inflamatorios
EA202090255A3 (ru) 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов
PH12016501066A1 (en) ROR GAMMA (ROYy) MODULATORS
BR112019009529A2 (pt) novos derivados de quinolina
CL2015001304A1 (es) Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
BR112017005393A2 (pt) composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição
EA201891861A1 (ru) 2-(морфолин-4-ил)-1,7-нафтиридины
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
MX2015013348A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
AR085324A1 (es) Composiciones de moleculas pesticidas y proceso de aplicacion de dichas composiciones para controlar acaros, insectos y otras plagas
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
BR112013017635A2 (pt) inibidores de cyp11b, cyp17 e/ou cyp21
UY30824A1 (es) Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones.
BR112012017382A2 (pt) compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica
ECSP099269A (es) Compuestos de fenilurea como inhibidores de epóxido hidrolasa soluble
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112019000486A2 (pt) composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase
CL2015001319A1 (es) Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
EA202090448A1 (ru) Дигидрооксадиазиноны
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112021026899A2 (pt) Compostos heterocíclicos
ME00957B (me) Derivati alkinil7-alkinil-1,8-naftirodoni, njihova priprema i primjena u liječenju

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]